Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Anti-Human Growth Hormone-Releasing Hormone (GHRH) Polyclonal Antibody CL8861AP CL8861AP-S Lot: 166121 DESCRIPTION: Growth hormone–releasing hormone (GHRH) is a 42 – 44 amino acid neuropeptide primarily produced in the arcuate nucleus of the hypothalamus. Secreted GHRH is carried to the anterior pituitary via the hypothalamohypophyseal portal system, where it binds its receptor (GHRHR) and stimulates growth-hormone (GH) release. GH is required for normal postnatal growth, bone growth, regulatory effects on protein, carbohydrate, and lipid metabolism1. Release of GHRH is pulsatile and as such leads to a similar release of GH2. PRESENTATION: 100 μg (CL8861AP) or 20 μg (CL8861AP-S) purified IgG buffered in PBS and 0.02% NaN3. (Purified from serum via Affinity Chromatography). For maximum recovery of contents, spin down tube before use. STORAGE/STABILITY: Store at + 4°C. For long term storage, aliquot and freeze unused portion at -20°C in volumes appropriate for single usage. Avoid freeze/thaw cycles. SPECIFICATION: Immunogen: 15 amino acid synthetic peptide located at the C-terminus of the 44 aa human GHRH neuropeptide. Specificity: This antibody is specific for human GHRH. IgG Class: Rabbit IgG Application: This antibody is suitable for use in ELISA (1:64K - 1:128K dilution) and Immunohistochemistry with paraffin embedded sections (4 μg/mL). This antibody has not been tested in other applications. REFERENCES: 1. Plotsky PM, Vale W. (1985) Patterns of growth hormone-releasing factor and somatostatin secretion into the hypophysial-portal circulation of the rat. Science. 230(4724):461-3. 2. Frohman LA, et al. (1990) Measurement of growth hormone-releasing hormone and somatostatin in hypothalamic-portal plasma of unanesthetized sheep. Spontaneous secretion and response to insulininduced hypoglycemia. J Clin Invest. 86(1):17-24. Optimum conditions for use of this antibody in analytical procedures should be established in each laboratory For Research Use Only JK 04/05/17